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Based on a newly established sequencing strategy fea-
tured by its efficiency, simplicity, and easy manipula-
tion, the sequences of four novel cyclotides (macrocyclic
knotted proteins) isolated from an Australian plant Vi-
ola hederaceaewere determined. The three-dimensional
solution structure of V. hederaceae leaf cyclotide-1 (vhl-
1), a leaf-specific expressed 31-residue cyclotide, has
been determined using two-dimensional 1H NMR spec-
troscopy. vhl-1 adopts a compact and well defined struc-
ture including a distorted triple-stranded -sheet, a
short 310 helical segment and several turns. It is stabi-
lized by three disulfide bonds, which, together with
backbone segments, form a cyclic cystine knot motif.
The three-disulfide bonds are almost completely buried
into the protein core, and the six cysteines contribute
only 3.8% to the molecular surface. A pH titration exper-
iment revealed that the folding of vhl-1 shows little pH
dependence and allowed the pKa of 3.0 for Glu
3 and 5.0
for Glu14 to be determined. Met7 was found to be oxi-
dized in the native form, consistent with the fact that its
side chain protrudes into the solvent, occupying 7.5% of
the molecular surface. vhl-1 shows anti-HIV activity
with an EC50 value of 0.87 M.
Cyclotides are a recently characterized family of naturally
occurring circular mini-proteins of 28 to 37 amino acid residues
isolated from plants of the Rubiaceae and Violaceae families (1,
2). Their head-to-tail backbone and six conserved cysteine res-
idues make up a topologically unique structure designated as a
cyclic cystine knot in which two disulfide bonds and their
connecting backbone segments form an embedded ring that is
penetrated by a third disulfide bond (3). Fig. 1 shows the
structure of kalata B1, the first example characterized in
the cyclotide family, and its sequence is presented in Table I.
The fact that cyclotides are exceptionally resistant to thermal
and proteolytic degradation has led to the suggestion that the
cyclic cystine knot motif contributes greatly to their stability.
By contrast, the amino acid sequences between the six cys-
teines, which form six loops that present on the surface of the
molecules, affect the surface characteristics and biological ac-
tivities of the cyclotides. The cyclotides have been divided into
two subfamilies, Mo¨bius and bracelet cyclotides (1, 4) based on
the presence or absence, respectively, of a cis-Pro peptide bond
in the circular peptide backbone.
The cyclotides show a diverse range of biological activities,
including uterotonic activity of kalata B1 from Oldenlandia
affinis DC (5, 6), the HIV 1 inhibitory activity of circulins from
Chassalia parvifolia Schum, cycloviolins from Leonia cymosa
Mart., and palicourein from Palicourea condensata Standl (7–
9), the antimicrobial activity of kalata B1, circulins A and B,
and cyclopsychotride A from Psychotria longipes Muell. Arg
(10), the cytotoxic activity of cycloviolacin O2 from Viola odo-
rata L. and vitri A from Viola tricolor L (11, 12)., the neuro-
tensin antagonistic activity of cyclopsychotride A (13), the he-
molytic activity of violapeptide I from Viola tricolor L (14), the
trypsin inhibitory activity of MCoTI-I and II from Momordica
cochinchinensis (15), and the insecticidal activity of kalata B1
and kalata B2 (16, 17). All of these cyclotides were originally
found through screening programs for biological activities or, in
the case of the uterotonic activity, from native medicine usage
(5). Some cyclotides, for example, kalata B1, circulins, and
cyclopsychotride A, effectively show several different inhibitory
activities, suggesting that the loops of one cyclotide molecule
may have various biological functions and can potentially bind
to different target sites. Perhaps most interesting is the finding
that kalata B1 and kalata B2 inhibit the growth and develop-
ment of Helicoverpa punctigera larvae, leading to the sugges-
tion that cyclotides play an important role in plant defense
against pests or pathogens (16, 17). The diverse bioactivities,
along with their unique structural characteristics, render the
cyclotides extremely important in terms of potential agro-
chemical or pharmaceutical applications (4, 16, 18).
The cyclotides, like many other defense proteins, are derived
from precursor polypeptides, which undergo a process of post-
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translational modification. Recently we reported the isolation
and characterization of cyclotide cDNA clones from V. odorata
(19). A single full-length cDNA transcript encodes one or several
cyclotides, which are separated by conserved peptide fragments
termed N-terminal repeats that may function in the cyclization
and folding of cyclotides (19). We also synthesized the N-terminal
repeats based on the cDNA clones and elucidated their -helical
solution structures by NMR spectroscopy. Interestingly the
N-terminal repeat sequences were not as conserved as those
predicted from cDNA clones from O. affinis (16). This might
result from the fact that the cDNAs from V. odorata encode both
subfamilies, Mo¨bius and bracelet cyclotides, instead of represent-
ing mainly one subfamily of cyclotides, as was the case for the
cDNAs isolated from O. affinis (16, 19).
To date, 50 cyclotides have been reported from a number of
species of the Rubiaceae and Violaceae plant families, and all
have molecular masses ranging from 2.8 to 3.5 kDa. A recent
study by HPLC and LC-MS on cyclotides from Viola hederaceae
revealed that up to 66 different masses, most likely correspond-
ing to the same number of cyclotides, were discerned in ex-
tracts of various parts of the plant (20). This suggests that the
cyclotides are a very diverse family of proteins and potentially
are much more common in plants than had previously been
realized. To expand our knowledge of structure-activity rela-
tionships of the cyclotides, we introduce a new strategy for
determining the sequence of cyclic disulfide rich peptides, re-
port the isolation and characterization of four novel cyclotides
from V. hederaceae, and present the solution structure of vhl-1,
one of the new cyclotides.
EXPERIMENTAL PROCEDURES
Isolation and Purification of vhl-1—Fresh whole plant of V. heder-
aceae was collected from a garden in Brisbane, Australia and separated
into different parts: leaves, petioles, flowers, pedicels, roots, bulbs, as
well as above and below ground runners. The leaves were homogenized
using a blender (Moulinex) and extracted with dichloromethane:metha-
nol (1:1) overnight. Plant debris was removed using a cotton plug. The
filtrate was repeatedly partitioned with dichloromethane and water.
The organic soluble fraction was discarded, and the methanol/water
layer was concentrated on a rotary evaporator (Bu¨cchi) prior to lyoph-
ilization. Then the mixture was diluted with distilled water to a final
methanol concentration 20% and lyophilized on a freeze-drier (Speed-
Vac). The dried material was redissolved in a minimal amount of buffer
A (0.05% trifluoroacetic acid prepared in distilled water). The solution
was then passed through a solid phase filter (Sartorius) before purifi-
cation using preparative RP-HPLC on an Agilent 1100 series system
with variable wavelength detector and Phenomenex Jupiter C18 col-
umn (250 22 mm, 5 m, 300 Å). Gradients of buffer A (0.05% aqueous
trifluoroacetic acid) and buffer B (90% acetonitrile, 0.05% trifluoroace-
tic acid) were employed with a flow rate of 8 ml/min and a gradient of
1% buffer B per minute. Further purification was performed using
semipreparative RP-HPLC on a Phenomenex Jupiter C18 column
(250  10 mm, 5 m, 300 Å) and using an analytical Phenomenex
Jupiter C18 column (250  4.6 mm, 5 m, 300 Å). The final purity was
examined with analytical RP-HPLC on a Grom column (150  2 mm, 3
m, equipped with a security-guard column) with a flow rate of 300
l/min. Masses were analyzed on a Micromass LCT mass spectrometer
equipped with an electrospray ionization source.
Aminoethylation of Cysteines—The reduction and alkylation of the
disulfide bonds was performed according to the method described in the
literature (21) with minor modification. 5 nmol of vhl-1 was reduced
with 0.4 mol of dithiothreitol in 200 l 0.25 M Tris-HCl, containing 1
mM EDTA and 8 M guanidine HCl (pH 8.5, 37 °C) under N2. After 2 h,
20 mol of bromoethylamine dissolved in 20 l of 0.25 M Tris-HCl,
containing 1 mM EDTA and 8 M guanidine HCl (pH 8.5) was added. The
reaction was incubated in a water bath at 37 °C in the dark under N2
overnight and terminated by injection onto RP-HPLC and eluted with a
linear gradient of 0–80% buffer B in 80 min. The molecular masses of
the collected fractions were confirmed by LCT-ESI-MS prior to lyophi-
lization and storage at 20 °C.
Reduction of vhl-1 and MALDI-MS Analysis—To 6 nmol of vhl-1 in
20 l of 0.1 M NH4HCO3 (pH 8.0), 1 l of 0.1 M TCEP was added, and the
solution was incubated at 65 °C for 10 min. The reduction was con-
firmed by MALDI-TOF-MS after desalting using Ziptips (Millipore),
which involved several washing steps followed by elution in 10 l of 80%
acetonitrile (0.5% formic acid). The desalted samples were mixed in a
1:1 ratio with matrix consisting of a saturated solution of -cyano-4-
hydroxycinnamic acid in 50% acetonitrile (0.5% formic acid). The in-
strument used was a Voyager DE-STR mass spectrometer (Applied
Biosystems). 200 shots per spectra were acquired in positive ion reflec-
tor mode. The laser intensity was set to 1800, the accelerating voltage
was set to 20,000 V; the grid voltage was set to 64% of the accelerating
voltage, and the delay time was 165 ns. The low mass gate was set to
500 Da. Data were collected between 500 and 5000 Da. Calibration was
undertaken using a peptide mixture obtained from Sigma Aldrich
(MSCal1).
Enzymatic Digestion and Nanospray MS-MS Sequencing—To the
reduced peptide, trypsin, endoproteinase GluC (endo-GluC), or a com-
bination of both were added to give a final peptide-to-enzyme ratio of
50:1. The trypsin incubation was allowed to proceed for 1 h, the endo-
GluC was over 3 h, while for the combined digestion trypsin was added
initially for 1 h followed by the addition of endo-GluC for a further 3 h.
The digestions were quenched by the addition of an equal volume of
0.5% formic acid and desalted using Ziptips (Millipore). Samples were
stored at 4 °C prior to analysis. The fragments resulting from the
digestion were examined first by MALDI-TOF-MS followed by sequenc-
ing by nanospray MS-MS on a QStar mass spectrometer. A capillary
voltage of 900 V was applied and spectra were acquired between m/z
60–2000 for both TOF spectra and product ion spectra. The collision
energy for peptide fragmentation was varied between 10 and 50 V,
depending on the size and charge of the ion. The Analyst software
program was used for data acquisition and processing. The MS-MS
spectra were examined and sequenced based on the presence of both b
and y series of ions present (N- and C-terminal fragments). The same
procedure was utilized for the sequencing of the three other novel
cyclotides isolated from V. hederaceae. Chymotrypsin digests using the
same conditions as for trypsin were also conducted to confirm the
results obtained for each of the peptide sequences.
NMR Experiments—The sample for NMR spectroscopy was prepared
by dissolving vhl-1 in 70% H2O, 25% CD3CN, and 5% D2O to a final
concentration of 1.4 mM, since aggregation of the peptide was observed
in 100% water. All spectra were recorded on Bruker ARX 500 or Bruker
ARX 600 spectrometers equipped with a shielded gradient unit, with
sample temperature in the range 283–330 K. All spectra were acquired
in phase-sensitive mode using time proportional phase incrementation
(22). For TOCSY (23), using MLEV-17 (24) with a mixing time of 80 ms,
and NOESY (25) with mixing times of 100, 200 and 250 ms, water
suppression was achieved using a WATERGATE (water suppression by
gradient-tailored excitation) (26) sequence. Double quantum-filtered
COSY (27) and E-COSY (28) were also recorded. Slowly exchanging
amide protons were identified by recording a series of one-dimensional
spectra and two-dimensional TOCSY spectra at 298 K over a period of
20 h immediately after dissolution of a sample in 25% CD3CN and 75%
D2O.
FIG. 1. Ribbon representation of kalata B1 structure. The cy-
clotide framework consists of six loops, separated by successive six
cysteines, which are numbered in Roman numerals according to their
appearance order in the linear precursor protein. The cyclic cystine knot
is made up by disulfide bond III-VI penetrating the ring formed by
disulfides I-IV and II-V and their connecting backbone segments.
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The pH dependence was monitored for vhl-1 at 298 K by altering the
sample pH from 2.0 to 6.0 by adding HCl or NaOH. The pKa of the
titrating Glu3 and Glu14 residues was determined for vhl-1 by nonlinear
curve fitting of the data points. The 3JHN-H coupling constants were
obtained from a high resolution one-dimensional spectrum and from
line shape analysis of the anti-phase cross-signal splitting in a high
resolution DQF-COSY spectrum.
All two-dimensional spectra were collected over 4096 data points in
the f2 dimension and 512 increments in the f1 and processed using
XWINNMR (Bruker) on a Silicon Graphics Octane work station. The f1
dimension was generally zero-filled to 2048 real data points, with the f1
and f2 dimensions being multiplied by a sine-squared function prior to
Fourier transformation. Chemical shifts were internally referenced to
sodium 2,2-dimethyl-2silapentane-5-sulfonate.
Structural Restraints—Distance restraints were derived primarily
from cross-peaks in a 250-ms mixing time NOESY spectrum recorded
at 298 K. The cross-peaks were analyzed and resonance assignments
were achieved using the program SPARKY.2 25 backbone dihedral
restraints were added on the basis of 3JHN-H coupling constants
derived from the splitting of the amide and  protons and were
constrained to 120 (30)° for 3JHN-H in the range 8.5  0.5 Hz
(residues 1, 3, 4, 5, 7, 8, 10, 19, 21, 24, and 30), 120 (15)° for
3JHN-H greater than 9.5 Hz (residues 26, 27), and 65 (30)° for
3JHN-H less than 5.8 Hz (residues 6, 9, 11, 14, 15, 16, and 31). One
additional constraint of 100 (80)° (residue 18) was applied where
the 3JHN-H coupling constant is 7.00 Hz, and the intraresidue
Hi-HNi NOE is weaker than the sequential Hi-HNi NOE. Residues
22, 23, 28, and 29 with intense Hi-HNi NOEs and
3JHN-H coupling
constants of 7 Hz were restrained to 50 (40)°. 3JH-H coupling
constants derived from an E-COSY spectrum, together with NOE
intensity patterns from the NOESY spectrum with a mixing time of
100 ms, were used to determine the stereospecific assignments of
-methylene protons and 17 1 dihedral angle restraints. Ten hydro-
gen bonds were determined based on slow exchange data and prelim-
inary structure calculations. 20 restraints of 1.7–2.2 and 2.7–3.2 Å for
these hydrogen bonds were added and used in the final structure
calculation.
Structure Calculation—Initial structures were calculated using DY-
ANA (30) based on NOE data output from SPARKY. After an iterative
process in which preliminary structures were used to resolve ambigu-
ities, sets of 50 structures were calculated using a torsion angle simu-
lated annealing protocol within the program CNS (31). This protocol
involved a high temperature phase comprising 4000 steps of 0.015 ps of
torsion angle dynamics, a cooling phase with 4000 steps of 0.015 ps of
torsion angle dynamics during which the temperature was lowered to
0 K, and finally an energy minimization phase comprising 500 steps of
Powell minimization. The resultant structures were subjected to fur-
ther molecular dynamics and energy minimization in a water shell (32).
A set of 20 structures with the lowest overall energy that had no
violations of distance restraints greater than 0.2 Å or dihedral angle
restraints greater than 3° was chosen to represent the structure of
vhl-1. Structures were visualized using the programMOLMOL (33) and
analyzed with PROMOTIF_NMR (34) and PROCHECK_NMR (35). The
20 final structures of vhl-1 and associated restraints have been depos-
ited in the Protein Data Bank (ID code: 1ZA8).
RESULTS
Isolation and Purification of Cyclotides—Cyclotides show
several defining characteristics, including late elution on
HPLC and a mass range from 2.8 to 3.5 kDa. Based on these
characteristics, we have established an effective and efficient
procedure to isolate and purify cyclotides from various compo-
nents of the crude plant extracts (16). In the current study, we
divided fresh collected plant material into eight parts (leaves,
petioles, flowers, pedicels, above ground runners, below ground
runners, bulbs, and roots) and used the extraction protocol to
obtain crude cyclotide extracts. RP-HPLC profiles of different
parts of V. hederaceae are shown in Fig. 2. Repeated RP-HPLC
resulted in the separation and purification of four novel cycloti-
des corresponding to chromatographic peaks 4, 5 (two pep-
tides), and 6. The molecular masses of these cyclotides deter-
mined as shown in Table I by electrospray ionization (ESI)
mass spectrometry revealed they were new when compared
with the molecular masses of known cyclotides. The cyclotide
corresponding to chromatographic peak 3 is expressed only in
leaves, but its mass of 3117.8 matches a reported cyclotide
cycloviolacin O10 isolated from V. odorata (1). Chromatographic
peak 7 corresponds to a cyclotide named vhr1, whose molecular
characterization was reported recently (20). Among the four
novel cyclotides, the two corresponding to peak 5 are expressed
in several different tissues and were designated as cyclovi-
olacins H2 and H3. The one with a relatively late retention
time corresponding to peak 6 is only expressed in leaves and
named as vhl-2 (V. hederaceae leaf cyclotide-2).
Special emphasis was put on a cyclotide vhl-1 with a reten-
tion time of 32.0 min (peak 4) as it is relatively abundant and
expressed specifically in leaves and not in any other parts of
the plant. From the crude extract of V. hederaceae leaves vhl-1
was isolated and purified to homogeneity by RP-HPLC as
shown in the last panel in Fig. 2. The yield of vhl-1 was about
1 mg/kg fresh plant material.
Amino Acid Sequence Analysis—Amino acid analysis of vhl-1
indicated that it is composed of 31 amino acids: 1 Ala, 6 Cys, 2
Glu or Gln, 2 Phe, 2 Gly, 3 Ile, 2 Lys, 1 Leu, 1 Met, 2 Asp or Asn,
5 Ser, 1 Thr, 2 Val and 1 Tyr. It shows resistance to enzymatic
cleavage by trypsin, consistent with the presence of a cyclic
cystine knot motif characteristic of all cyclotides. After reduc-
tion and alkylation, each reduced and S-aminoethylated cys-
teine contributes to an increment of molecular mass by 44 Da.
Nanospray MS and LC-ESI-MS analysis of the native (3330,
mono-isotopic mass) and S-aminoethylated peptide (3594)
demonstrated that, like other cyclotides, six cysteines are pres-
ent in three intramolecular disulfide bonds. Tryptic cleavage
was then carried out on the alkylated peptide in an attempt to
use a recently proposed “loop sequencing” method for determin-
ing the primary structure of cyclotides (21, 36). However, this
approach resulted in very complicated enzymatic fragments,
implying that, besides the six alkylated cysteines, several other
positively charged amino acid residues exist in the primary
structure. All of the alkylated cysteines and positive residues
provide cleavage sites for trypsin and, as a result, produce
additional fragments, complicating the MS-MS data.
An alternative strategy outlined in Fig. 3, which includes
both enzymatic digestion and MS-MS fragmentation, was used
to complete the sequence analysis. The native cyclotide was
reduced by TCEP and subjected to enzymatic digestion di-
rectly, without alkylation of the cysteines. The reduction of the
peptide was confirmed by the observation of peaks at m/z
11123 and 8344, which correspond to a molecular mass of
3336 Da due to the addition of six protons to the native peptide.
Digestion of the reduced peptide with endo-GluC gave rise to
two major peaks at m/z 627.72 and 707.33 corresponding to
two fragments with masses of 1253.5 and 2118.9 and implying
the presence of two glutamic acid residues. Several other peaks
with relatively low intensities were also produced after diges-
tion by trypsin or a combination of trypsin and endo-GluC.
The study of the MS-MS fragmentation of the first fragment
at m/z 627.72 resulted in completion of its amino acid se-
quence as shown in Fig. 4A, suggesting that it consists of 11
amino acid residues with the sequence SCAF*ISFCFTE. The
b2 ion of the fragment at m/z 191 could be either SC or CS.
However, it was determined to be SC by comparison with
known cyclotides and further confirmed by NMR spectroscopy.
The second fragment at m/z 707.33 was difficult to analyze by
MS-MS fragmentation because of its length. However, two
partial sequences from both N-terminal (VIGCSCKNKV-) and
C-terminal (-LNSISCGE) were observed as highlighted in Fig.
4B and in the supplemental Table I. The b and y ions greater
2 Goddard, T. D. and Kneller, D. G., SPARKY 3 program, University
of California, San Francisco.
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than 5% in relative intensity are labeled in Fig. 4, and a
number of ions that allow full sequence elucidation are also
present in low abundance (see supplemental Table I). The third
enzymatic fragment resulting from digestion by trypsin and
endo-GluC at m/z 715.32 was selected and subject to MS-MS
fragmentation. Fig. 4C indicates that the sequence NKVCYLN-
SISCGE was deduced, which is actually a part of the second
fragment and, together with the information of the N-terminal
sequence of the second fragment, led to the establishment of
the sequence VIGCSCKNKVCYLNSISCGE (m/z 707.33) of
the second fragment.
The amino acid composition of the proposed sequence formed
by combining the three fragments is in agreement with the
amino acid analysis, except for the residue Met. The mass
difference between ion b4 and b3 in fragment 1 is 147 Da, sug-
gesting that the amino acid residue is Phe as marked by the *.
FIG. 2. Purification of vhl-1. RP-HPLC profiles of cyclotide extracts from various tissues (leaves, flowers, petioles, pedicels, above ground
runners, below ground runners, bulbs, and roots) of V. hederaceae. 5 mg/ml solutions of crude cyclotide extracts from different plant parts were
made and centrifuged at 10,000  g for 10 min. Then 8-l supernatant samples were injected and analyzed on an analytical C-18 Grom column
(150 2 mm, 3 m; flow rate: 300 l per min) with a linear acetonitrile gradient (10–80%) of buffer B (90% acetonitrile, 0.05% trifluoroacetic acid)
in 40 min. The purity of vhl-1 shown in the last panel, obtained from the leaves of the plant, was assessed by RP-HPLC on the same analytical
C-18 column using the same method.
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However, in two dimensional TOCSY and NOESY spectra of
vhl-1, the spin system of this residue shows the presence of two
 and two  protons, none of which have any correlations to
aromatic protons as shown in Fig. 5A. This result, along with
the presence of Met from amino acid analysis and the informa-
tion that this residue has a mass of 147 Da (16 Da addition of
131 Da for Met), indicates that this residue is a mono-oxidized
Met, instead of Phe. This conclusion is fully consistent with the
results of amino acid analysis and the “sequential walk” in
NOESY spectra. The identification of the two fragments de-
rived from the endo-GluC digestion, VIGCSCKNKVCYLNSIS-
CGE (m/z 707.33) and SCAM*ISFCFTE (m/z 627.72) rather
than SCAF*ISFCFTE was therefore successfully completed.
To determine whether the mono-oxidized Met exists in the
native cyclotide or is oxidized during the process of isolation
and purification, we extracted fresh leaves using methanol
under N2 for different time periods and investigated the mass
of the cyclotide by MALDI-MS spectrometry. The mass of 3330
was detected in samples extracted quickly under non-oxidizng
conditions, suggesting that the methionine exists naturally in
oxidized form in the plant.
The sequences of the other three novel cyclotides vhl-2 and
cycloviolacins H2 and H3 as shown in Table I were also estab-
lished using a similar procedure.
Structure Elucidation of vhl-1—The NMR solution structure
of vhl-1 was determined based on homonuclear two-dimen-
sional NMR experiments including TOCSY, NOESY, DQF-
COSY, and E-COSY. As shown in Fig. 5, the cross-peaks in the
two-dimensional NMR fingerprint regions are well dispersed
and could be unambiguously identified for spin system assign-
ments in the TOCSY spectrum and for sequential connectivi-
ties in the NOESY spectrum. The unbroken sequential walk
confirms unequivocally the head-to-tail circular backbone of
the peptide and the amino acid sequence from MS-MS frag-
mentation and amino acid analysis. The structure was calcu-
lated from a total of 232 interproton distances derived from
NOESY spectra, including 103 sequential, 51 medium range
and 78 long range NOE restraints. On the basis of coupling
constants, 25  and 17 1 dihedral angle restraints were in-
cluded in the structure calculations. Finally, 20 upper limit
hydrogen bond restraints for 10 hydrogen bonds derived from
amide exchange experiments and preliminary structures were
included.
A set of 50 structures was calculated using torsion angle
simulated annealing. The 20 structures with the lowest overall
energy that had no violations of distance restraints greater
than 0.2 Å or dihedral angle restraints greater than 3° were
chosen to represent the structure of vhl-1. Fig. 6A shows the
NMR ensemble of the final 20 energy-minimized conformers
and the structural statistics for this family are summarized in
Table II. The mean global backbone root mean square deviation
is 0.28 Å for residues involved in secondary structure elements
and 0.32 Å for all residues. For heavy atoms the root mean
TABLE I
New cyclotides characterized in this work and selected examples of known cyclotides
Conserved cysteine residues are boxed and presented in bold.
a All masses are provided as mono-isotopic mass.
b V. hederaceae leaf cyclotide (vhl).
c Non-tissue-specific expressed cyclotide. Note that cyclotides that are specific to a particular tissue are named accordingly, while those present
in a range of tissues are designated using previously described nomenclature (1).
FIG. 3. Strategy employed for amino acid sequence analysis.
Disulfide bonds were reduced by TCEP.M*, mono-oxidized methionine.
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FIG. 4. MS-MS fragmentation re-
corded by nanospray MS-MS spec-
trometry. The masses were calculated on
the basis of the mass-to-charge ratio. A, a
double charged peak at m/z 627.72 cor-
responding to the molecular mass 1253.5
Da of the first fragment. B, a triple
charged peak atm/z 707.33matching the
second fragment with a molecular mass of
2118.9 Da. C, a double charged peak at
m/z 715.32 representing the third frag-
ment with a molecular mass of 1428.6 Da.
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square deviation is 1.14 Å for all residues. The small root mean
square deviation values over the molecules for the backbone
and heavy atoms of all the residues, as well as the minimal
restraint violations, shows that vhl-1 adopts a well defined
structure.
The peptide backbone of vhl-1 is folded back onto itself and is
stabilized by three disulfide bonds. The three-dimensional
structure comprises a central  sheet region (colored cyan in
Fig. 6B), consisting of residues Cys18–Lys21 in loop 4 and
Val24–Leu27 in loops 5/6, which, together with a type I -turn
centering at residues Asn22 and Lys23, forms a -hairpin. This
motif, combined with a third distorted strand involving resi-
dues Glu3, Ser4, and Cys5, makes up a triple-strand antiparal-
lel -sheets flanked by a short 310 helix (Glu
14–Ile16) in loop 3.
Two additional type I-like -turns are present in the regions of
Ala6–Ser9 and Leu27–Ile30. The extended loop 2 protrudes onto
the surface of the molecule, while loop 6 is twisted 90° rela-
tive to the triple-strand antiparallel -sheet base. The second-
ary structural elements are recognized in a majority of the 20
lowest energy structures by the program PROMOTIF (34).
Disulfide Connectivity Pattern—Previous studies suggested
a common pattern for the disulfide bond connectivity of I-IV,
II-V, and III-VI in cyclotides (6). This connectivity was further
confirmed based on the extensive investigation of 1 dihedral
angles of the cysteine residues and direct chemical evidence
using a novel approach for disulfide analysis, involving partial
reduction and stepwise alkylation (36, 37). In this study, we
determined the 1 dihedral angle restraints for the six cys-
teines by analyzing the 3JH-H coupling constants and NOEs
intensities, all of which are consistent with those of kalata B1,
cycloviolacin O1, and vhr1 (20, 37). Therefore, we used this
pattern of disulfide connectivity as shown in Fig. 6B, a knotted
arrangement, in the structure calculations, instead of the lad-
dered one suggested as an alternative (38). The peptide struc-
ture obtained is in excellent agreement with these experimen-
tal restraints.
Determining the pKa Values of Glu
3 and Glu14 of vhl-1—The
cyclotide vhl-1 contains two glutamic acid residues, namely
Glu3 and Glu14. The former residue is absolutely conserved
throughout the cyclotide family, suggesting a crucial structural
or functional role. Their pKa values were determined by mon-
itoring the chemical shifts of other nearby protons (39). Record-
ing TOCSY spectra as a function of pH revealed that the
majority of amide chemical shifts fluctuate by less than 0.1
ppm over the pH range 2–6, indicating that the protonation or
deprotonation of carboxylate groups does not affect the overall
structure. However, the amide protons of residues Phe12 and
Thr13 shifted downfield by more than 3 and 1.5 ppm, respec-
tively, over the indicated pH range as shown in Fig. 7A. Similar
shifts were also observed in kalata B1 and cycloviolacin O1
(37). This is because as pH increases, the deprotonated carbox-
ylate of Glu3 functions as a proton acceptor to form hydrogen
bonds with the proximal amides of Phe12 and Thr13, causing
them to shift downfield. Fig. 7B shows the hydrogen bond
interaction between amides of Phe12 and Thr13 and carboxylate
of Glu3. In addition, the Thr13 hydroxyl proton was observed in
the NOESY spectrum recorded at pH 3.2, indicating that it is
involved in a side chain-side chain hydrogen bond interaction.
These interactions account for the relatively low pKa value of
3.0 for Glu3 (40). We also obtained information on the pKa of
Glu14 by analyzing the titration curve for Cys11 shown in Fig.
7A. The Cys11 amide is slightly affected by the deprotonation of
Glu3 upon increasing pH from 2.0 to 4.0 and shifts upfield by
0.5 ppm. Fig. 7C shows the relative orientation of this amide.
On interaction with the deprotonated carboxylate group of
Glu14 on increasing pH from 4.0 to 6.0, the amide of Cys11 shifts
back downfield by 0.4 ppm, displaying a second sigmoidal
curve and allowing a pKa value of 5.0 for Glu
14 to be deter-
mined. Compared with the pKa value of 4.5 as expected for a
Glu carboxylate in a random peptide, this slight pKa shift may
be caused by electrostatic interactions of this residue with the
proximal Glu3 (41).
DISCUSSION
Although cyclotides were first discovered in a limited num-
ber of Rubiaceae plant species, recent studies have revealed
they are widespread in the plant kingdom and especially abun-
dant in the genus Viola of the family Violaceae (1, 12, 14, 21,
42). More generally, circular proteins of various types have
been discovered in bacteria, plants, and animals in recent years
(2). Some cyclotides can be expressed in different plants, or
even in different tissues of one plant species, as is the case for
HPLC peaks 1 and 2 of V. hederaceae shown in Fig. 2, which
correspond to cyclotides kalata B1 and kalata S, respectively.
In fact, these two cyclotides constitute two main components in
almost all parts of the plant except in flowers. However, other
cyclotides are expressed only in one or several tissues, for
FIG. 5. TOCSY and NOESY spectra of vhl-1. Fingerprint regions
of 80 ms TOCSY spectrum (A) and 250 ms NOESY spectrum in 75%
H2O, 20% CD3CN, and 5% D2O (B) at 298 K. Spin systems are shown in
the TOCSY spectrum and the sequential connectivities in the NOESY
spectrum. The one-letter code for amino acids as well as the residue
number is used for the sequence assignments. Phe12 has a NH chemical
shift of 10.9 ppm and is not included in the diagram to improve visibility
of the other peaks. Note that its downfield shift is a strong indicator of
its hydrogen bonding.
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example, in aerial parts. In this study, attention was focused on
those cyclotides that occur in only one plant tissue, because
these molecules might have unique structures, bioactivities, or
physiological functions.
As can be seen in Fig. 2, the RP-HPLC profile of leaves of
V. hederaceae is quite different from those of other tissues in
that there are three tissue-specific cyclotides (peaks 3, 4, and
6). Repeated RP-HPLC on the crude extracts of V. hederaceae
leaves resulted in the isolation of vhl-1 as well as three other
novel cyclotides vhl-2, cycloviolacin H2, and cycloviolacin H3.
Amino acid analysis and sequencing clearly indicated that
vhl-1 is composed of 31 amino acid residues and shares the
same highly conserved six cysteine residues as all other mem-
bers of the cyclotide family, suggesting that it adopts a sim-
ilar three-dimensional structure. It belongs to the bracelet
subfamily of cyclotides due to the absence of a cis-Pro peptide
bond in loop 5 (1). Comparison of the vhl-1 sequence with
known cyclotides allows some conclusions to be drawn re-
garding the six successive loops. The peptide possesses highly
conserved loops 1 and 4, which consist of three residues, GES,
and one residue, S, respectively. This conservation likely
occurs because loops 1 and 4 form the backbone segments of
the embedded ring of the cyclic cystine knot and their amino
acid residues play significant roles in the structural stability
and bioactivities of cyclotides (data not shown). Loop 5 con-
tains four residues, KNKV, with two positively charged res-
idues in close proximity, which is in agreement with 11
known cyclotides in the bracelet subfamily.
However, vhl-1 shows some distinguishing characteristics in
terms of its amino acid composition and sequence. It possesses
an extended loop 2, with five amino acid residues AM*ISF,
compared with four residues in loop 2 of all other cyclotides
characterized so far. vhl-1 is also the first cyclotide containing
an oxidized Met. Mass spectral investigation of vhl-1 by
MALDI-MS confirmed the cyclotide contains the mono-oxidized
derivative of Met with a mass of 3330, instead of 3314 Da. Loop
3, comprising six residues FTEVIG, shows the common feature
of a majority of residues being hydrophobic as well as a rela-
tively conserved hydroxyl-containing Thr and highly conserved
last residue Gly. However, it differs from other cyclotides in
that it contains a second Glu residue, which contributes an
FIG. 6. Structure of vhl-1. A, stereo
view of the 20 lowest energy structures of
vhl-1 derived from NMR restraint data,
superimposed over the N, C, and C at-
oms of all 31 residues. The first and every
tenth residue are numbered. B, ribbon
representation of the structure of vhl-1,
showing its key features of a cyclic cystine
knot motif and secondary structural
elements.
TABLE II
Structural statistics for the family of 20 vhl-1 structures
Energies (kcal mol)
Overall 982.33  16.33
Bonds 6.99  0.67
Angles 42.41  4.16
Improper 6.16  1.32
Van der Waals 67.60  5.21
NOE 9.98  2.01
cDih 0.65  0.27
Dihedral 125.10  7.26
Electrostatic 1106.22  18.99
Atomic rms derivation (Å)
Mean global backbone 0.32  0.08
Mean global heavy 1.14  0.14
Distance restraints
Intraresidue (i  j 	 0) 87
Sequential (i  j 	 1) 103
Medium range (i  j  5) 51
Long range (i  j 
 5) 78
Hydrogen bonds 20
Total 339
Dihedral angle restraints
 25
1 17
Total 42
Violations from experimental
restraints
NOE violations exceeding 0.20 Å 0
Diheral violations exceeding 3.0° 0
Ramachandran
Most favored 75%
Additionally allowed 21.3%
Generously allowed 3.7%
Disallowed 0.0%
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additional cleavage site for endo-GluC. Furthermore, loop 6 has
an unusual characteristic that the last residue Ser replaces the
Pro shared by all other bracelet subfamily cyclotides. The
structural roles of these residues will be discussed later in
relation to the structure of vhl-1.
New Strategy for Sequencing Analysis—Cyclotides are a
unique, disulfide-rich family of proteins with a circular back-
bone and cyclic cystine knot motif and as a consequence are
impervious to proteolytic digestion and cannot be directly se-
quenced by Edman degradation. Previous methods for amino
acid sequencing were all based on reduction and alkylation of
peptides followed by enzymatic cleavage for Edman degrada-
tion or MS-MS analysis. Multiple handling and purification
procedures in these methods, as well as a tendency to fail to
yield informative data, made it imperative to devise a new
strategy. In the current study, the sample preparation process
for MS-MS fragmentation is very simple and practical. The ion
suppression effect of TCEP in the reaction solution was easily
diminished through the use of Ziptips (Millipore) for desalting.
The procedure involving the reduction and subsequent cleav-
age by one or more proteolytic enzymes occurs in one reaction
vessel on a nanomolar scale and requires only a single desalt-
ing step followed by direct analysis by MALDI-MS and nano-
spray MS or a combination of these two complementary tech-
niques. The resulting data were readily interpretable and
allowed the rapid elucidation of the primary sequence of vhl-1,
as well as other novel cyclotides, which were otherwise difficult
to sequence by existing methods.
Sequence and Structure Homology with Other Cyclotides—
Sequence alignment of the cyclotides in Table I indicates that
in addition to six cysteines, some residues such as Glu3 in loop
1 and Gly17 in loop 3 are extremely conserved in both Mo¨bius
and bracelet subfamilies. Glu3 and Gly17 appear to be impor-
tant because the Glu3 side chain, through extensive hydrogen
bonding, forms a part of the folding scaffold (37). Gly17 is
involved in a connecting site between helix and strand for
bracelet cyclotides and between turn and -sheet for Mo¨bius
cyclotides. Another conserved residue throughout the cyclotide
family is Asn (Asn28 for vhl-1) in loop 6, which is likely involved
in cleavage and cyclization from the precursor protein to pro-
duce the mature peptide. The additional Glu14 in loop 3 of vhl-1
appears not to significantly affect the molecular folding be-
cause its carboxylate group is solvent exposed and has little
capacity to form hydrogen bonds with internal amides. By
contrast with other cyclotides, a hydrophilic loop 6 is present,
since the NSIS sequence segment replaces hydrophobic resi-
dues shared by almost all other cyclotides. This segment twists
and protrudes from the surface.
To date, although about 50 cyclotides have been character-
ized, three-dimensional structures of only eight cyclotides
namely kalata B1 and B2 (6, 17), circulins A and B (43, 44),
cycloviolacin O1 (1, 37), palicourein (45), vhr1 (20), and vhl-1
have been determined using NMR techniques. The last six
cyclotides belong to the bracelet subfamily and have six or
seven residues in loop 3. These residues are involved in a short
310 helical conformation, as is the case for cycloviolacin O1,
vhr1, palicourein, and vhl-1. In contrast, kalata B1 and B2, the
sole examples from the Mo¨bius subfamily that have been struc-
turally characterized, contain only four residues in loop 3,
which are involved in a type II -turn (17, 37).
Like other known cyclotides, the overall structure of vhl-1
adopts a compact fold with three disulfide bonds involving
formation of a cystine knot buried into the protein core. Anal-
ysis of the surface-exposed residues shows that the six cysteine
FIG. 7. Hydrogen bonding interac-
tions. A, pH titrations monitoring the
changes in chemical shifts at backbone
amide protons. B and C, the cyclotide
backbone and disulfide bonds are pre-
sented in line format, with the residues
involved in hydrogen bonding interac-
tions displayed in bold representation.
Hydrogen bonding networks are high-
lighted with shaded circles.
Structure of a Novel Cyclotide 22403
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
residues contribute only 3.8% to the surface of the molecule.
However, hydrophobic residues constitute 57.3% of the molec-
ular surface, compared with 39.0% for kalata B1 and 57.0% for
vhr1 and cycloviolacin O1. These data explain the late HPLC
retention times of cyclotides compared with the majority of
other peptides. Despite the larger hydrophobic patch on the
molecular surface of vhl-1 compared with vhr1, it eluted 2.5
min earlier than vhr1 under the same chromatographic condi-
tions. This is most likely because vhl-1 contains an additional
Lys and Glu, both of which are exposed on the molecular
surface. Among the 57.3% molecular surface constituted by 19
residues including two Gly, 7.5% is attributed to Met7. This
indicates that the side chain of Met7 protrudes onto the molec-
ular surface, making it easily oxidized.
The surface representation of the vhl-1 structure (supple-
mental Fig. 1) reveals that hydrophobic residues involving
loops 2 and 3 almost form a continuous surface, which is only
disturbed by a core close to Glu3. Lys21, Asn22, and Lys23 in loop
5 and Asn28, Ser29, and Ser31 in loop 6, however, form a hydro-
philic region punctuated by hydrophobic patches from Val24
and Ile30.
Implications for Biological Activities—Among the large num-
ber of cyclotides discovered to date, only two cyclotides contain
Met. Varv B isolated from Viola arvensis (46) contains a Met in
loop 5 as shown in Table I. The reduced Met in Varv B suggests
that the side chain may be involved in the hydrophobic core and
not solvent exposed. By contrast, the oxidized Met7 in vhl-1
results from its side chain protrusion into the molecular sur-
face and may play a role in the physiological functions. In
general, oxidation of Met residues in proteins is associated with
aging as well as in pathological conditions and results in in-
creasing their susceptibility to proteolysis (47). But, it seems
the latter is not the case for vhl-1 as there was no evidence for
degraded forms in the extracts. The oxidation of Met in pro-
teins to Met sulfoxide is a reversible reaction mediated by
methionine sulfoxide reductase (MsrA; EC 1.8.4.6) (48). One
study suggested that oxidation and reduction of methionine
could play a dynamic role in cellular signal transduction pro-
cesses in a variety of systems (48), while other studies led to
another suggestion that Met residues may serve as antioxi-
dants and that MsrA acts to reduce the oxidized Met. MsrA and
its corresponding substrate-oxidized Met form an efficient
means to repair oxidative damage in vivo (49, 50). Plants re-
spond to virulent pathogens by producing active oxygen spe-
cies, such as oxidized Met (51). Some pathogens, on the other
hand, can express MsrA to repair oxidative damage and as a
result can survive the host environment (52). Whether vhl-1
plays such a role among the suite of cyclotides found in
V. hederaceae remains to be determined.
vhl-1 was tested for anti-microbial activity against several
microorganisms (Escherichia coli, Staphylococcus aureus, and
Candida albicans) but showed no inhibitory activity against
these microorganisms. This indicates that, if the theory that
active oxygen constituents play a key role in plant defense is
true, the mechanism of peptides containing oxidized Met
against pathogen invasion is different from that applied to the
anti-microbial bioassay. vhl-1 was also screened for anti-HIV
activity, and it inhibited the cytopathic effects of HIV infection
with an EC50 value of 0.87 M. A range of other cyclotides have
been reported to exhibit anti-HIV activity with a similar order
of magnitude (29, 53). Clearly there is no physiological reason
for a plant to need protection against HIV, but the anti-viral
activity may be an indicator of an as yet undiscovered role of
the cyclotides as protective agents against plant viruses.
Finally, the extremely stable and compact structures of cy-
clotides, as well as the flexibility of both amino acid composi-
tion and sequences in loops 2, 5, and 6, provides a highly
suitable framework for drug design. By analyzing structural
features of a range of different cyclotides, it may prove possible
to graft bioactive segments from other proteins or peptides,
which are normally unstable and have poor bioavailability, into
this framework, to form novel pharmaceutical molecules. In the
current study, we have enriched the knowledge of the cyclotide
family by characterizing novel cyclotides and determining the
solution structure of cyclotide vhl-1.
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Supplementary Table 1: Nanospray MS-MS Analysis of Vhl-1 Digested by Trypsin
and Endoproteinase Glu-C
Ion type: b m/z z Ion type: y m/z z
SC 191.0 1 E 148.1 1
SCA 262.1 1 TE 249.1 1
SCAM* 409.1 1 FTE 396.1 1
SCAM*I 522.2 1 CFTE 499.2 1
SCAM*IS 609.2 1 FCFTE 646.2 1
SCAM*ISF 756.3 1 SFCFTE 733.2 1
SCAM*ISFC 859.3 1 ISFCFTE 846.3 1
SCAM*ISFCF 1006.3 1
SCAM*ISFCFT 1107.4 1
Fragment 1
m/z 627.7
(Mass 1253.5)
SCAM*ISFCFTE 627.7 2
E 148.1 1
VI 213.2 1 GE 205.1 1
VIG 270.2 1 CGE 308.1 1
VIGC 373.2 1 SCGE 395.1 1
VIGCS 460.2 1 ISCGE 508.1 1
VIGCSC 563.2 1 SISCGE 595.2 1
VIGCSCK 691.2 1 NSISCGE 709.2 1
VIGCSCKN 805.3 1
VIGCSCKNK 933.3 1
VIGCSCKNKV 1032.5 1
Fragment 2 - LNSISCGE 649.8 2 Fragment 2 - VIGC 874.3 2
Fragment 2 - NSISCGE 706.3 2 Fragment 2 - VIG 925.8 2
Fragment 2 - SISCGE 763.3 2 Fragment 2 - VI 954.4 2
Fragment 2 - ISCGE 806.9 2 Fragment 2 - V 1010.9 2
Fragment 2 - SCGE 863.4 2 Fragment 2 707.3 3
Fragment 2 - CGE 906.9 2
Fragment 2 - GE 958.4 2
Fragment 2 - E 986.9 2
Fragment 2 §
m/z 707.3
(Mass 2118.9)
Fragment 2 707.3 3
E 148.1 1
NK 243.1 1 GE 205.1 1
NKV 342.2 1 CGE 308.1 1
NKVC 445.2 1 SCGE 395.1 1
NKVCY 608.3 1 ISCGE 508.2 1
NKVCYL 721.3 1 SISCGE 595.2 1
NKVCYLN 835.4 1 NSISCGE 709.3 1
NKVCYLNS 922.4 1 LNSISCGE 822.3 1
NKVCYLNSI 1035.5 1 YLNSISCGE 985.4 1
NKVCYLNSIS 1122.5 1 CYLNSISCGE 1088.4 1
NKVCYLNSISC 1225.5 1 VCYLNSISCGE 1187.4 1
NKVCYLNSISCG 1282.5 1
Fragment 3
m/z 715.3
(Mass 1428.6)
NKVCYLNSISCGE 715.3 2
* Mono-oxidised Met
§ Sequence of fragment 2: VIGCSCKNKVCYLNSISCGE
Supplementary Figure 1: Surface representation of vhl-1.
A, showing the distribution of hydrophobic residues colored green, negatively charged
residues colored red, positively charged residues colored dark blue, polar residues colored
light grey, Met colored light blue and cysteine residues colored yellow. B, C and D, the views
are rotated 90°, 180° and 270° about the vertical axis, respectively.
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